SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

Veerle P W M Wijtvliet; Sonja Verheyden; Barbara Depreter; Christine Heylen; Elke Coeman; Steven Abrams; Benedicte Y De Winter; Annick Massart; Rachel Hellemans; Lissa Pipeleers; Frans H J Claas; Kevin K Ariën; Karl Martin Wissing; Daniel Abramowicz; Kristien J Ledeganck

doi:10.1016/j.trim.2022.101670

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

Veerle P W M Wijtvliet, Sonja Verheyden, Barbara Depreter, Christine Heylen, Elke Coeman, Steven Abrams, Benedicte Y De Winter, Annick Massart, Rachel Hellemans, Lissa Pipeleers, Frans H J Claas, Kevin K Ariën, Karl Martin Wissing, Daniel Abramowicz, Kristien J Ledeganck

Virology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Abstract

BACKGROUND: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.

METHODS: In the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.

RESULTS: Overall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.

CONCLUSION: The current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.

Original language	English
Article number	101670
Journal	Transplant immunology
Volume	74
Number of pages	7
ISSN	0966-3274
DOIs	https://doi.org/10.1016/j.trim.2022.101670
Publication status	Published - 2022

Keywords

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines
COVID-19/prevention & control
Graft Rejection
HLA Antigens/genetics
Histocompatibility Antigens
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Humans
RNA, Messenger
Renal Dialysis
SARS-CoV-2
Vaccination
rho Guanine Nucleotide Dissociation Inhibitor beta

Access to Document

10.1016/j.trim.2022.101670

Cite this

Wijtvliet, V. P. W. M., Verheyden, S., Depreter, B., Heylen, C., Coeman, E., Abrams, S., De Winter, B. Y., Massart, A., Hellemans, R., Pipeleers, L., Claas, F. H. J., Ariën, K. K., Wissing, K. M., Abramowicz, D., & Ledeganck, K. J. (2022). SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies. Transplant immunology, 74, Article 101670. https://doi.org/10.1016/j.trim.2022.101670

@article{f2def2886d734a0489f283544f8010f7,

title = "SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies",

abstract = "BACKGROUND: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.METHODS: In the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.RESULTS: Overall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.CONCLUSION: The current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.",

keywords = "2019-nCoV Vaccine mRNA-1273, Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, COVID-19/prevention & control, Graft Rejection, HLA Antigens/genetics, Histocompatibility Antigens, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, Humans, RNA, Messenger, Renal Dialysis, SARS-CoV-2, Vaccination, rho Guanine Nucleotide Dissociation Inhibitor beta",

author = "Wijtvliet, {Veerle P W M} and Sonja Verheyden and Barbara Depreter and Christine Heylen and Elke Coeman and Steven Abrams and {De Winter}, {Benedicte Y} and Annick Massart and Rachel Hellemans and Lissa Pipeleers and Claas, {Frans H J} and Ari{\"e}n, {Kevin K} and Wissing, {Karl Martin} and Daniel Abramowicz and Ledeganck, {Kristien J}",

note = "NPP; Copyright {\textcopyright} 2022. Published by Elsevier B.V.",

year = "2022",

doi = "10.1016/j.trim.2022.101670",

language = "English",

volume = "74",

journal = "Transplant immunology",

issn = "0966-3274",

publisher = "Elsevier",

}

Wijtvliet, VPWM, Verheyden, S, Depreter, B, Heylen, C, Coeman, E, Abrams, S, De Winter, BY, Massart, A, Hellemans, R, Pipeleers, L, Claas, FHJ, Ariën, KK, Wissing, KM, Abramowicz, D & Ledeganck, KJ 2022, 'SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies', Transplant immunology, vol. 74, 101670. https://doi.org/10.1016/j.trim.2022.101670

TY - JOUR

T1 - SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

AU - Wijtvliet, Veerle P W M

AU - Verheyden, Sonja

AU - Depreter, Barbara

AU - Heylen, Christine

AU - Coeman, Elke

AU - Abrams, Steven

AU - De Winter, Benedicte Y

AU - Massart, Annick

AU - Hellemans, Rachel

AU - Pipeleers, Lissa

AU - Claas, Frans H J

AU - Ariën, Kevin K

AU - Wissing, Karl Martin

AU - Abramowicz, Daniel

AU - Ledeganck, Kristien J

PY - 2022

Y1 - 2022

N2 - BACKGROUND: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.METHODS: In the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.RESULTS: Overall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.CONCLUSION: The current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.

AB - BACKGROUND: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.METHODS: In the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.RESULTS: Overall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.CONCLUSION: The current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.

KW - 2019-nCoV Vaccine mRNA-1273

KW - Antibodies, Viral

KW - BNT162 Vaccine

KW - COVID-19 Vaccines

KW - COVID-19/prevention & control

KW - Graft Rejection

KW - HLA Antigens/genetics

KW - Histocompatibility Antigens

KW - Histocompatibility Antigens Class I

KW - Histocompatibility Antigens Class II

KW - Humans

KW - RNA, Messenger

KW - Renal Dialysis

KW - SARS-CoV-2

KW - Vaccination

KW - rho Guanine Nucleotide Dissociation Inhibitor beta

U2 - 10.1016/j.trim.2022.101670

DO - 10.1016/j.trim.2022.101670

M3 - A1: Web of Science-article

C2 - 35835296

SN - 0966-3274

VL - 74

JO - Transplant immunology

JF - Transplant immunology

M1 - 101670

ER -

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

Abstract

Keywords

Access to Document

Fingerprint

Cite this